AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Withdrawn) A diagnostic agent for leukemia~~a disease caused by the tumorigenic change of a hematopoietic cell~~, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

2. (Withdrawn) The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

3. (Withdrawn) The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

4. (Withdrawn) The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

5. (Withdrawn) The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')2, a single chain antibody and a disulfide stabilized antibody.

6. (Withdrawn) The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

7. (Withdrawn) A therapeutic agent for leukemia~~a disease caused by the tumorigenic change of a hematopoietic cell~~, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

8. (Withdrawn) The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

9. (Withdrawn) The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

10. (Withdrawn) The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

11. (Withdrawn) The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')2, a single chain antibody and a disulfide stabilized antibody.

12. (Withdrawn) The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

13. (Withdrawn) A method for diagnosing leukemia~~a disease caused by the tumorigenic change of a hematopoietic cell~~, comprising reacting cells or tissues of a person with an anti-human VEGF receptor Flt-1 antibody to immunologically detect or determine a human VEGF receptor Flt-1 existing in the cells or tissues.

14. (Withdrawn) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

15. (Withdrawn) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

16. (Withdrawn) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

17. (Withdrawn) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')2, a single chain antibody and a disulfide stabilized antibody.

18. (Withdrawn) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

Claim 19. (Canceled)

Claim 20. (Canceled)

Claim 21. (Canceled)

22. (Currently Amended) A method for treating ~~a disease caused by the tumorigenic change of a hematopoietic cell~~leukemia, comprising selecting a patient in need thereof and administering to a patient in need thereof an effective amount of an anti-human VEGF receptor Flt-1 antibody.

23. (Currently Amended) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

24. (Previously Presented) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

25. (Previously Presented) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

26. (Previously Presented) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')2, a single chain antibody and a disulfide stabilized antibody.

27. (Currently Amended) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope or a ~~radioisotope, a~~ protein or a low molecular weight anticancer agent by a chemical or genetic engineering means.

Claim 28. (Cancel)

29. (Currently Amended) A method for treating ~~a disease caused by the tumorigenic change of a hematopoietic cell~~leukemia, comprising selecting a patient in need thereof and administering to the ~~to a~~ patient ~~in need thereof~~ an effective amount of ~~an humana~~ a human chimeric anti-human VEGF receptor Flt-1 antibody.

30. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG type.

31. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG1 type.

Claim 32. (Cancel)